Ildong Pharmaceutical said Monday that it has received sales approval for Telostop Plus Tab., hypertension, and hyperlipidemia treatment, from the Ministry of Food and Drug Safety.

Telostop Plus is a treatment, which combines three compounds -- telmisartan, a blood pressure lowering angiotensin II receptor blocker (ARB) agent, amlodipine, a calcium channel blocker (CCB), and rosuvastatin, a lipid-lowering agent.

This product increases drug compliance for patients as it takes care of all three medications that patients who have hypertension and hypercholesterolemia, with a single pill.

The company confirmed the safety and efficacy of the drug through a phase 3 clinical trial from November 2015 to June 2017. Clinical trials showed that three dosing regimens developed by the company were more effective against hypertension and hyperlipidemia when compared to the other two regimens groups –telmisartan and amlodipine and telmisartan and rosuvastatin.

“Hypertension and hyperlipemia, which are typical cardiovascular risk factors, have a high correlation with one another,” a company official said. “In such cases the number of drugs that a patient needs to take increases. Therefore, a combination drug can increase the convenience of patients.”

The company plans to start the marketing of the drug in August.